Humana Inc.

- Humana is maintaining dividend levels and limiting share repurchases to offset employee stock compensation dilution. - They intend to increase dividends and share repurchases when cash flows and funding capacity grow with the execution of their plan. - The company is pursuing noncore asset divestitures to help fund strategic acquisitions, with more updates expected in the coming months. - Recent initiatives include issuing $1 billion junior subordinated notes in March to fund 2027 maturities. - Additional efforts to optimize the balance sheet involve subsidiary reinsurance and augmenting legal entity structures, mitigating over $3 billion in capital contribution requirements for 2026. - Any potential cash obligations related to partner Welsh Carson's put options (around $1 billion to $1.5 billion in 2027) are included in Humana's funding plan. - Overall, Humana is actively managing debt and equity strategies but no immediate equity issuance is mentioned explicitly.

- Humana is pursuing noncore asset divestitures to help fund strategic acquisitions and expects to share more news on this in the coming months. (Page 3) - They have executed initiatives to optimize the balance sheet, including subsidiary reinsurance and legal entity restructuring, mitigating over $3 billion in capital contribution requirements for 2026. (Page 3) - Issued $1 billion junior subordinated notes in March, expected to fund 2027 maturities, indicating capital management and funding for future investments. (Page 3) - Continuing to evaluate a pipeline of initiatives to further strengthen the balance sheet, supporting ongoing and future strategic investments. (Page 3)

- Membership growth trajectory is on track, with dynamic management of distribution and growth if needed (Page 2). - Solid growth across CenterWell's lines of business: pharmacy, primary care (including recent Max Health acquisition), and home health (Page 6). - Expansion of CenterWell’s reach into new critical markets through acquisitions like Max Health (Page 2, 6). - Continued Medicaid membership growth (~50,000 lives) from new program starts in Michigan, Illinois, and South Carolina (Page 2). - Anticipated doubling of individual Medicare Advantage (MA) margin in 2026, reflecting improved operational performance and pricing discipline (Page 2). - Stable and compelling MA margin expected, unlocking earnings potential by 2028 (Page 3). - Growth expected from diversified business lines beyond benefits, supported by mature transformation efforts (Page 12). - Emphasis on retention and quality improvements to support sustainable long-term growth (Page 5).

- Humana expects to double individual Medicare Advantage (MA) margins in 2026, adjusted for Stars performance. - Focus is on returning to a sustainable margin of at least 3% by 2028, with progress to be made in 2027. - Pricing discipline and tight cost management, including operating cost reductions and tactical/strategic measures, support margin improvement. - Operating leverage continues to be a meaningful contributor to earnings growth through 2028. - Membership growth trajectory remains on track, which supports stable and compelling MA margins. - Capital allocation includes strategic acquisitions (e.g., Max Health) and noncore asset divestitures to fund growth. - Guidance for 2026 PDP (Prescription Drug Plan) business remains in line with expectations, supporting overall earnings stability. - Management remains cautious but confident in navigating bids and benefit adjustments to meet long-term earnings targets.

The provided document does not include specific information regarding the company's current or expected orderbook or pending orders. The discussion primarily focuses on: - Operational progress and transformation office roles - Medicare Advantage (MA) membership growth and performance - Margin and bid strategy outlook for 2027 and 2028 - Cost management and operating leverage initiatives - Claims monitoring, funding environment, and benefit adjustments - Capital deployment and balance sheet enhancements No explicit reference or data on orderbook, pending orders, or backlog is mentioned in the material on pages 5, 8, 9, 10, and 12.